USO 21320
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer who have Progressed after Treatment with Osimertinib (ONC-003)
Disease Types: Lung Cancer Research
Eligibility Requirements:
Unresectable stage III or IV NSCLC
• EGFR mutation-positive
• Phase 2: measurable disease per RECIST 1.1.
• Phase 2a:
• Cohort 1 must have progression on osimertinib
alone
• Cohort 2 must have progression after treatment
with osimertinib, pemetrexed and a platin or single
agent osimertinib followed by combination
pemetrexed and a platin with or without osimertinib
• Phase 2b: osimertinib treatment must be the only
prior systemic treatment.
For more information on this study CLICK HERE .
Available at: